Brought to you by 
Molecular Insight completes $65.1mm IPO
02 Oct 2012
Executive Summary
More than a year after filing an S-1, radiotherapeutics company Molecular Insight Pharmaceuticals has completed its initial public offering of 5mm shares at $14 each--the low-end of its anticipated $14-16 range--netting $65.1mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Molecular Insight completes $65.1mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice